08:26 AM EDT, 09/16/2025 (MT Newswires) -- Mira Pharmaceuticals ( MIRA ) said Tuesday that its oral drug candidate Ketamir-2 restored normalized behavior in stressed rats in a proof-of-concept study using an accepted model for post-traumatic stress disorder.

The drug is currently under evaluation in an ongoing phase 1 clinical trial for neuropathic pain, where it has shown a favorable safety profile, the company said.

Mira Chief Executive Erez Aminov said the results support its decision to broaden evaluation of Ketamir-2 beyond neuropathic pain into neuropsychiatric disorders such as PTSD and to explore partnerships with military and government institutions.

In the study, the rats were exposed twice to bobcat urine, which is known to induce depression-like symptoms in the animal, and later dosed orally with Ketamir-2 for five consecutive days, which reversed PTSD-like behaviors, the company said.